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Abstract
Background: Approximately half of the world’s population is infected with Helicobacter pylori (H.pylori), a bacterium
shown to be linked with a series of gastrointestinal diseases. A growing number of systematic reviews (SRs) have been
published comparing the effectiveness of different treatments for H.pylori infection but have not reached a consistent
conclusion. The objective of this study is to provide an overview of SRs of pharmacological therapies for the eradication
of H.pylori.
Methods: Major electronic databases were searched to identify relevant SRs published between 2002 and February
2016. Studies were considered eligible if they included RCTs comparing different pharmacological regimens for treating
patients diagnosed as H.pylori infected and pooled the eradication rates in a meta-analysis. A modified version of the ‘A
Measurement Tool to Assess Systematic Reviews’ (AMSTAR) was used to assess the methodological quality. A Bayesian
random effects network meta-analysis (NMA) was conducted to compare the different proton pump inhibitors (PPI)
within triple therapy.
Results: 30 SRs with pairwise meta-analysis were included. In triple therapy, the NMA ranked the esomeprazole to be
the most effective PPI, followed by rabeprazole, while no difference was observed among the three old generations of
PPI for the eradication of H.pylori. When comparing triple and bismuth-based therapy, the relative effectiveness
appeared to be dependent on the choice of antibiotics within the triple therapy; moxifloxacin or levofloxacin-based
triple therapy were both associated with greater effectiveness than bismuth-based therapy as a second-line treatment,
while bismuth-based therapy achieved similar or greater eradication rate compared to clarithromycin-based therapy.
Inconsistent findings were reported regarding the use of levofloxacin/moxifloxacin in the first-line treatment; this could
be due to the varied resistant rate to different antibiotics across regions and populations. Critical appraisal showed a
low-moderate level of overall methodological quality of included studies.
Conclusions: Our analysis suggests that the new generation of PPIs and use of moxifloxacin or levofloxacin within
triple therapy as second-line treatment were associated with greater effectiveness. Given the varied antibiotic resistant
rate across regions, the appropriateness of pooling results together in meta-analysis should be carefully considered and
the recommendation of the choice of antibiotics should be localized.
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Background
Helicobacter pylori (H.pylori) is one of the most com-
mon human infections with a worldwide prevalence of
approximately 50 %. In the United States (US) and
Europe, the prevalence of H.pylori is estimated to be
20 % to 50 %, varying in different socioeconomic, age
and ethnic groups and geography [1, 2]. In developing
countries, the prevalence has been reported to be as
high as 70 % [3]. H.pylori is usually latent and asymp-
tomatic; however, increasing evidence has demonstrated
the link between H.pylori infection and the pathogenesis
of a series of upper gastrointestinal diseases: functional
dyspepsia, chronic gastritis, peptic ulcer disease, gastric
cancer and gastric mucosa-associated lymphoid-tissue
lymphoma [4–9].
Eradication of H.pylori has been shown to be associ-
ated with increased rate of peptic ulcer healing and re-
duced risk of gastric cancer [10, 11]. Standard triple
therapy, which includes a proton pump inhibitor (PPI),
clarithromycin, and amoxicillin or metronidazole, is
recommended as first-line eradication therapy for
H.pylori infection in clinical guidelines worldwide [12–
15]. A treatment alternative also widely recommended
is bismuth-based quadruple therapy, which contains a
PPI or H2 receptor antagonist (H2RA), bismuth, metro-
nidazole, and tetracycline. Other treatment options in-
clude varying individual drugs within the triple therapy
and quadruple therapy based regimens. More recently,
sequential therapy of these multiple treatment options
also has been introduced. In the US, the American Col-
lege of Gastroenterology guideline (2007) recommends
clarithromycin-based triple therapy for first-line eradi-
cation in patients who have not previously been treated
with clarithromycin and are not allergic to penicillin.
For patients who are allergic to penicillin or have previ-
ously received a macrolide antibiotic, a bismuth quad-
ruple therapy is preferred [14].
Although these recommendations specified the type
of antibiotics in the regimen, the choice of PPIs was
not specified. Based on the available evidence at the
time when the guidelines were produced, the relative
effectiveness of PPIs was assumed to be comparable.
Furthermore, in recent years, a decline in the effective-
ness of the treatment regimens has been observed due
to increasing clarithromycin resistance; this may have
an impact on the relative effectiveness of these treat-
ment strategies [16]. A 12-year retrospective study pub-
lished in 2008 showed that the eradication rate of
standard therapy decreased from 90.6 % in 1997 to
74.8 % [17].
In the past decade, several systematic reviews have
evaluated the effectiveness of individual specific pharma-
cological regimens for H.pylori eradication. These re-
views compared the eradication rate by different PPIs
and antibiotics, triple versus quadruple therapy, or PPI
versus H2RA, but the conclusions of these reviews were
not always consistent.
The Scottish Intercollegiate Guidelines Network (SIGN)
published their recommendations on H.pylori eradication
in the dyspepsia guideline in 2003 and is due to update
their guidance [18]. This study aims to systematically
evaluate the current evidence (since 2003) on the effect-
iveness of H.pylori eradication therapies for the patients
diagnosed as H.pylori infection through an overview of
systematic reviews.
Methods
An overview of systematic reviews was carried out ac-
cording to the general principles of systematic reviewing
methodology [19]. A Bayesian network meta-analysis
(NMA) was conducted to compare the eradication rates
by using different PPIs within triple therapy.
Eligibility criteria
All systematic reviews comparing different drug therap-
ies for the eradication of H.pylori infection that fulfilled
the following criteria were included:
 Patient — studies of adult patients who were naïve
to treatment (first-line therapy) or have previous
treatment failures (second-line therapy).
 Intervention/Comparator — studies comparing any
pharmacological regimens.
 Outcome measure — studies reporting pooled
eradication rates measured by urea breathe testing
or gastric mucosal biopsy four weeks after completion
of treatment, as the primary outcome. Secondary
outcome measures may include adverse events rates
and rates of discontinuation of therapy due to severe
adverse events.
 Design — systematic reviews and meta-analyses of
data from randomized controlled trials (RCTs).
Exclusion criteria
Studies were excluded if they focused on comparing the
variation of dose or duration of the same drug combin-
ation; if no meta-analysis was conducted; meta-analysis
included observational studies; or the included RCTs in
the meta-analysis were not clearly specified. Conference
abstracts were excluded due to lack of details for data
extraction and quality assessment. Studies on furazoli-
done were excluded because it is no longer available in
the US and the United Kingdom (UK) due to severe side
effects. No language exclusions were applied. As this
work was initiated by the SIGN guideline update, studies
published prior to 2002 were excluded.
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Search strategy
Four major electronic databases were searched: MED-
LINE, EMBASE, the Cochrane Library and the Database
of abstracts of review of effects. Relevant keywords were
used to develop appropriate search strategies; these are
shown in the Additional file 1. The primary search was
carried out in November 2012 and updated in March
2016.
Study selection
Two reviewers (JM and YX) independently reviewed the
titles and abstracts of all retrieved studies for identifica-
tion of potentially relevant systematic reviews. After the
initial screening, the full texts of studies deemed relevant
were obtained and reviewed in detail. The discrepancy
was addressed by discussion or a third reviewer (OW).
Reference list of included studies was also checked to
identify any potentially relevant studies that may not
have been identified by the electronic searching.
Data extraction
For each included systematic review, the following data
were extracted by two reviewers independently: first au-
thor, publication year and country; objective; search
database and selection criteria; number of included stud-
ies in the review and meta-analysis; number of patients
in the meta-analysis; patient characteristics; intervention
and comparison; outcomes including eradication rate,
adverse events rate, therapy discontinuation rate. In
addition, as the resistant rate to antibiotics differs across
regions, the country of the RCTs included in the meta-
analysis was also extracted when the focus of the com-
parison was involved with antibiotics. To conduct the
NMA, we also extracted data from the individual RCTs
in the included systematic reviews, including: interven-
tions in comparison, the total number of people in each
arm and the number of people of which H.pylori had
been eradicated.
Quality assessment
To assess methodological quality of the included system-
atic reviews, a modified version of the ‘A Measurement
Tool to Assess Systematic Reviews’ (AMSTAR) checklist
[20] was used by two reviewers (JM and YX) independ-
ently to examine the following 11 aspects: (1) clearly de-
fined research question; (2) study selection and data
extraction carried out by two independent reviewers; (3)
comprehensive literature search; (4) clear selection cri-
teria; (5) list of included and excluded studies; (6) study
characteristics appropriately extracted; (7) quality assess-
ment documented; (8) results of quality assessment ap-
propriately considered in reaching conclusions; (9)
results combined appropriately; (10) publication bias
assessed; (11) conflicts of interest declared. Studies were
graded as “high quality (++)”, “acceptable (+)” or “low
quality (0)”, based on the overall risk of bias and the
likelihood that results may be changed by further
research.
Network meta-analysis (NMA)
A Bayesian random effect NMA was conducted to com-
pare and rank all the PPIs within the triple therapy
based on the eradication rates. When more than two in-
terventions are being evaluated, conventional pairwise
meta-analysis is limited in that it requires direct head-
to-head evidence between interventions. In contrast,
NMA allows the estimation of relative effects between
multiple alternative interventions by incorporating both
direct and indirect evidence [21, 22]. The NMA model
used in this study is shown in Additional file 2. The odds
ratios (ORs) for all pairwise comparisons of each treat-
ment were calculated and presented in an interval plot.
The median of the posterior distribution along with
95 % credible intervals (95%CrI) was reported. In
addition, the PPIs were ranked based on their probability
to be considered the best for the outcome of eradication
rate of H.pylori.
Two sets of vague priors, uniform and inverse Gamma,
were used for the Bayesian model, which were burned-in
for 27,000 and 8,000 Markov Chain Monte Carlo itera-
tions respectively until the convergence was met based on
the Gelman-Rubin-Brooke statistic (within 1+/− 0.05). A
further approximately 40,000 iterations were run until the
MC error became lower than 5 % standard error and the
results became stable. The median of the posterior distri-
bution and credible intervals for ORs was reported. The
analysis was performed using WinBUGS 1.4.3 [23].
Results
Results of search and selection
The search identified 1690 studies, of which 30 studies
were included in this overview of systematic reviews. The
flowchart of the screening process is shown in Fig. 1. The
excluded studies at full-text screening stage are listed in
Additional file 3: Table S1 with reasons for exclusion.
Systematic reviews included in analysis
All the included studies were published between 2002
and 2015 in English, with the exception of three studies,
which were published in Chinese [24–26]. Six studies
exclusively evaluated second-line treatment for patients
with at least one prior course of treatment failure [27–
32]; 12 studies focused on treatment naive patients [25,
26, 33–42]; the remaining systematic reviews included
RCTs for both first-line and second-line treatment. 13
studies evaluated treatments in patients with comorbid
gastric diseases including peptic ulcer disease, duodenal
ulcer, functional dyspepsia, chronic gastritis or other
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non-ulcer diseases [24, 27, 37–40, 43–49] (the remaining
studies did not provide such data). In addition to the
eradication rate, 15 systematic reviews also compared
adverse events rates [25, 28–38, 41, 47, 50] and six com-
pared the discontinuity rate (compliance rate) [25, 29–
31, 37, 50]. The pooled eradication rates of different reg-
imens in all of the included systematic reviews ranged
between 47 % (data from three RCTs relating to stand-
ard triple therapy [30]) and 94 % (data from one RCT
relating to esomeprazole-based triple therapy [46]) by
intention to treat (ITT) analysis.
Based on the treatment regimens under comparison,
the included studies were classified into the following
five categories:
 Triple therapy with different PPIs
 Triple therapy with different antibiotics
 Triple therapy versus bismuth-based therapy
 PPI versus H2RA in triple therapy
 Other drug therapies
Triple therapy with different PPIs
Seven studies evaluated the impact of different PPIs
within a triple therapy regimen on H.pylori eradication
rate (Table 1) [24, 42–46, 51]. These included both new
(esomeprazole, rabeprazole) and older generations of
PPIs (omeprazole, pantoprazole, lansoprazole); overall,
the results were mixed, but a time trend was observed
that studies published from 2006 onwards [24, 42, 46]
suggested consistently that new generation of PPIs
achieved greater eradication rate than the older genera-
tions. Amongst the new PPIs, the reported eradication
rates ranged from 77 % (data from nine RCTs relating to
rabeprazole-based triple therapy [43]) to 94 % (data from
one RCT relating to esomeprazole-based triple therapy
[46]); for the older generation PPIs, the reported eradica-
tion rates ranged from 75 % (data from four RCTs relat-
ing to omeprazole-based triple therapy [51]) to 88 %
(data from two RCTs relating to omeprazole-based triple
therapy [51]). Five studies compared esomeprazole with
older generation PPIs in the triple therapy, of which,
Fig. 1 Flowchart showing the process of selecting systematic reviews on effectiveness of Helicobacter pylori eradication based on eligibility criteria
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Table 1 Characteristics of systematic reviews comparing triple therapy with different PPIs (n = 7)
Author, year, country Last search date Disease Interventionc Comparatorc No. of studies
in MA
No. of patients
in MA
Eradication rates Eradication rates odds
ratio (95 % CI) by ITT
Quality
assessmentb
Gisbert et al. 2003-r Spain [43] Sep 2002 HP infection; PUD/
NUD/not reported
Rabeprazole Omeprazole/
Lansoprazole
12 2226 79 % vs. 77 % 1.15 (0.93–1.42) +
Rabeprazole Omeprazole 9 1475 77 % vs. 77 % 1.03 (0.81–1.32)
Rabeprazole Lansoprazole 7 1095 82 % vs. 79 % 1.20 (0.87–1.64)
Vergara et al. 2003 Spain [51] Sep 2002 HP infection Omeprazole Lansoprazole 4 1085 74.7 % vs. 76 %; 0.91 (0.69–1.21)a +
Omeprazole Rabeprazole 4 825 77.9 % vs. 81.2 % 0.81 (0.58–1.15)a
Omeprazole Esomeprazole 2 833 87.7 % vs. 89 % 0.89 (0.58–1.35)a
Lansoprazole Rabeprazole 3 550 81 % vs. 85.7 % 0.77 (0.48–1.22)a
Gisbert et al. 2004 Spain [44] Jun 2003 HP infection; PUD
+/−NUD
Esomeprazole Omeprazole 4 1292 85 % vs. 82 % 1.19 (0.81–1.74) +
Gisbert et al. 2004 Spain [45] Sep 2002 HP infection; PUD
+/−NUD
Pantoprazole Omeprazole/
Lansoprazole
7 1137 83 % vs. 81 % 1.00 (0.61–1.64) +
Pantoprazole Omeprazole 1 974 83 % vs. 82 % 0.91 (0.49–1.69)
Pantoprazole Lansoprazole 2 258 78 % vs. 75 % 1.22 (0.68–2.17)
Wang et al. 2006 China [24] Jul 2006 HP infection; DU,
NUD, PUD
Esomeprazole Omeprazole 11 2048 85.6 % vs. 81.6 % 1.30 (1.02–1.65) 0
Wang X et al. 2006 China [46] 2000–2005
(published date)
HP infection; PUD/
NUD
Esomeprazole Omeprazole/
Pantoprazole
11 2146 86 % vs. 81 % 1.39 (1.09–1.75) 0
Esomeprazole Omeprazole 10 1946 85 % vs. 82 % 1.29 (1.01–1.65)
Esomeprazole Pantoprazole 1 200 94 % vs. 82 % 3.44 (1.30–9.07)
McNicholl et al. 2012 Spain [42] Oct 2011 HP infection; naïve
to therapy
Rabeprazole Omeprazole/
Lansoprazole/
pantoprazole
21 2945 80.5 % vs. 76.2 % 1.21 (1.02–1.42) 0
Esomeprazole Omeprazole/
Lansoprazole/
pantoprazole
12 2598 82.3 % vs. 77.6 % 1.32 (1.01–1.73)
Rabeprazole Esomeprazole 5 1574 76.7 % vs. 78.7 % 0.90 (0.70–1.17)
HP H.pylori, PPI proton pump inhibitor, PUD peptic ulcer disease, NUD non-ulcer dyspepsia, MA meta-analysis, ITT intention to treat, CI confidence interval
a Peto OR is reported here
b Quality assessment: high quality (++): majority of criteria met, little or no risk of bias and results unlikely to be changed by further research. Acceptable (+): most criteria met, some flaws in the study with an
associated risk of bias and conclusions may change in the light of further studies. Low quality (0): either most criteria not met or significant flaws relating to key aspects of study design, and conclusions likely to
change in the light of further studies
c The antibiotics are the same type and same dose for each arm of the RCTs
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three reported a statistically significant benefit of esome-
prazole in H.pylori eradication with OR of approximately
1.3 [24, 42, 46]. A similar effect was reported in one of
the three studies comparing the effectiveness of the
rabeprazole with the older generation PPIs (OR 1.21;
95%CI 1.02–1.42) [42]. Only one study compared the ef-
fectiveness of esomeprazole with rabeprazole and found
no difference in eradication rate (OR 0.90; 95%CI 0.70–
1.17) [42]. Similarly, no difference was observed when
comparing within older generation PPIs [45, 51].
A diagram of the PPI network is given in Fig. 2. Over-
all, 57 trials were included in the NMA analysis. None of
the trials compared rabeprazole with pantoprazole, or
lansoprazole with esomeprazole. In contrast, esomepra-
zole was compared with omeprazole in 15 trials. In our
analysis omeprazole was used as the reference treatment
since direct trials existed comparing omeprazole and
each of the other PPIs and it was the most commonly
used PPI in the triple therapy for H.pylori eradication.
Esomeprazole was ranked first in the probability best
test, with OR to be 1.29 (95 % credible interval 1.08–
1.56) when compared with omeprazole, followed by
rabeprazole (Table 2). The three old generations of PPIs
showed similar effectiveness. The OR and interval plot
for each pair of the mixed comparisons of different PPIs
is shown in Fig. 3.
Triple therapy with different antibiotics
Seven studies evaluated the impact of different antibi-
otics within a triple therapy for the first-line treatment
[25, 26, 33–37] and one study evaluated the antibiotics
for both first-line and second-line treatment [47]
(Table 3). Clarithromycin was used as a comparator in
all the studies while the intervention antibiotics included
levofloxacin [25, 26, 35–37], azithromycin [33] and mox-
ifloxacin [34]. Five studies compared levofloxacin-based
triple therapy with standard triple therapy for first-line
treatment [25, 26, 35–37], among which two studies re-
ported improved eradication rates with levofloxacin [25,
26] while the other three studies showed no difference
between the two regimens [35–37]. Similarly, for moxi-
floxacin, two systematic reviews reached conflict conclu-
sions when comparing it with standard triple therapy for
first-line treatment [34, 47]. The two systematic reviews
included three same RCTs while one of them included
an additional RCT from China [34]. With the inclusion
of this RCT, the pooled result showed moxifloxacin was
associated with greater eradication rate for the naïve
patient (OR 1.13; 95%CI 1.01–1.27) [34] while no differ-
ence was shown in another study (OR 1.80; 95%CI 0.71–
4.55) [47]. The use of moxifloxacin as second-line treat-
ment was evaluated in one study which showed that the
moxifloxacin-based triple therapy achieved greater eradi-
cation rate than the clarithromycin-based therapy (OR
1.78; 95%CI 1.16–2.73) [47]. In addition to levofloxacin
and moxifloxacin, one study evaluated azithromycin-
based triple therapy versus standard triple therapy as
first-line treatment and did not find a difference [33].
In addition to the eradication rates, adverse events
rates were also compared in seven studies, such as nau-
sea, metallic taste and other gastrointestinal tract dis-
comforts [25, 33–37, 47]. Compared to clarithromycin,
the risk of adverse events was approximately halved with
azithromycin (OR 0.58; 95%CI 0.41–0.82) [33]. Two
studies compared the adverse events between moxifloxa-
cin and clarithromycin containing triple therapy; one
showed lower adverse events rate associated with moxi-
floxacin (OR 0.45; 95%CI 0.26–0.77) [47] while the other
Fig. 2 Network diagram. Number represents the number of trials available for that direct comparison
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did not show any difference [34]. For levofloxacin, one
study showed there were reduced adverse events rate
(OR 0.57; 95%CI 0.44–0.74) [25] while three studies re-
ported no difference when comparing to the standard
therapy [35–37].
Triple therapy versus bismuth-based therapy
Nine studies compared the effectiveness, adverse events
rate and therapy discontinuation rates between triple
therapy and bismuth-based therapy [27–32, 38, 39, 50].
The study characteristics are presented in Table 4. For
the bismuth-based therapies, seven studies evaluated
bismuth-based quadruple therapy [29–32, 38, 39, 50],
one evaluated ranitidine bismuth citrate (RBC) [27] and
another one evaluated both quadruple therapy and
RBC [28]. Overall, the quadruple therapy was associ-
ated with similar or greater eradication rate than
standard triple therapy; however when levofloxacin or
moxifloxacin was contained in the triple therapy, the
reverse was observed.
Two of the nine studies focused on treatment naive
patients, and no difference in eradication rates was
found between triple and quadruple therapy. The pri-
mary antibiotics used in both studies was clarithromycin
[38, 39]. The remaining seven studies compared second-
line therapy for patients with previous treatment failures
[27–32, 50]. The primary antibiotics used in triple ther-
apy varied: two studies evaluated clarithromycin [27, 50],
one study with moxifloxacin [31], three studies with
levofloxacin [28, 29, 32], and one study compared all of
the three [30]. Clarithromycin-containing triple therapy
was associated with lower eradication rates than bismuth-
based therapy in two studies [27, 30] while one study
showed no difference [50]. In contrast, moxifloxacin-
containing triple therapy was suggested to achieve greater
effectiveness than bismuth-based therapy [30, 31]. Similar
Table 2 Rank order of effectiveness of PPIs for H.pylori eradication
Rank Generation of PPI PPI Probability best
(standard deviation)
OR (95 % credible Interval)
Comparator: Omeprazole
1 New Esomeprazole 0.820 (0.384) 1.29 (1.08 – 1.56)
2 New Rabeprazole 0.170 (0.375) 1.77 (0.99 – 1.39)
3 Old Pantoprazole 0.008 (0.087) 0.94 (0.72 – 1.22)
4 Old Lansoprazole 0.003 (0.050) 0.93 (0.74 – 1.16)
5 Old Omeprazole 0.0003 (0.018) 1
Fig. 3 Odds ratios and interval plot of mixed treatment comparisons between PPIs for H.pylori eradication
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to moxifloxacin, triple therapy with levofloxacin appeared
to be more effective than bismuth-based therapy, however
statistically significant finding was only reported in one of
the four studies (OR 1.18; 95%CI 1.08–1.29) [29].
The adverse events around the bismuth-based therapy
included diarrhea, abdominal pain, dark stools, dizziness,
headache, nausea, metallic taste and nausea [52]. Seven
studies reported adverse events of the compared regi-
mens [28–32, 38, 50]. The pooled adverse event rates of
clarithromycin-based triple therapy ranged from 35.4 %
[50] to 37 % [38], 10.1 % [31] to 16.75 % [30] for levo-
floxacin or moxifloxacin-based triple therapy, and
27.8 % [31] to 44 % [28] for bismuth-based therapy. Five
studies showed a lower risk of adverse events of levo-
floxacin/moxifloxacin compared with the bismuth-based
regimen with ORs ranging from 0.27 to 0.51 [28–32],
and one study favoured bismuth when comparing with
clarithromycin triple therapy [50]. One study classified
adverse events by severity and reported much lower risk
favouring levofloxacin compared with bismuth therapy
when including only severe adverse events (OR 0.20;
95%CI 0.06–0.67) [28]. Furthermore, the discontinuation
rate of triple therapy using moxifloxacin and levofloxa-
cin was statistically significantly lower than bismuth-
based therapy in three of the four studies [29–31].
PPI versus H2RA in triple therapy
Three studies compared the effectiveness of PPI versus
H2RA within a triple therapy (Table 5) [40, 41, 53]. One
systematic review based on 20 RCTs with 2374 patients
showed PPI was associated with greater effectiveness
than H2RA (OR 1.31; 95%CI 1.09–1.58) [40]. Another
study of 12 RCTs did not show any difference between
the two, but its subgroup analysis based on six RCTs
suggested PPI-based triple therapy reached higher
eradication rates than H2RA when clarithromycin was
not contained [53]. A recent systematic review of three
RCTs compared lafutidine versus lansoprazole-
containing triple therapy and reported no difference be-
tween the two regimens [41].
Other drug therapies
One study evaluated the impact of adding metronidazole
or tinidazole (concomitant quadruple therapy) on stand-
ard triple therapy and reported greater eradication rates
with concomitant therapy (OR 2.36; 95%CI 1.67–3.34)
[48]. One study based on 14 RCTs assessed the combin-
ation of tetracycline and amoxicillin in triple therapy/
quadruple therapy and found no difference in eradica-
tion rate when compared to other regimens when the
two drugs were not combined [49]. One Japanese study
evaluated the effectiveness of supplementation with
rebamipide and found it was associated with greater
eradication rate compared to rebamipide not-containing
regimens (OR 1.59; 95%CI 1.14–2.22) [54]. The charac-
teristics of these studies are presented in Table 6.
Quality assessment
The overall quality of the included systematic reviews
was graded as low to moderate with a higher risk of bias
(Fig. 4). This was primarily due to insufficient reporting
and poor methodological approaches. The majority of
the reviews met five to eight criteria out of the 11 total
AMSTAR criteria. The criteria that were frequently not
fulfilled included: (1) transparent study selection process
and reference of excluded studies; (2) adequate reporting
of the population characteristics; (3) using quality appro-
priately in making conclusions; (4) assessing publication
bias when applicable. The detailed assessment for each
Fig. 4 Overall performance of included systematic reviews for each AMSTAR critical appraisal criteria
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Table 3 Characteristics of systematic reviews comparing triple therapy with different antibiotics (n = 8)
Author, Year, country Last search
date
Disease Countries of
included RCTsc
Intervention Comparator No. of
studies
in MA
No. of
patients
in MA
Eradication
rates by ITT
Eradication rates odds
ratio (95 % CI) by ITT
Quality
assessmentb
Zhang et al. 2008
China [25]
May 2008 HP infection;
naïve to
treatment;
PUD/NUD
China (8), Italy
(3)
Levofloxacin-containing
triple: levofloxacin+
Standard triple:
clarithromycin+
11 1926 Not
reported
1.56 (1.25–1.94) 0
+same PPI(Ome/panto/esome) + another one antibiotic
(furazolidone/amoxicillin/azithromycin/metronidazole/
tinidazole)
Dong et al. 2009
China [33]
May 2009 HP infection;
naïve to
treatment
China (4), Italy
(5), Korea,
Russia, France,
Croatia, US
Azithromycin-containing
triple: azithromycin+ + one
antibiotic (levofloxacin/
amoxicillin/metronidazole)+
Azithromycin NOT-
containing triple: + two
antibiotics (amoxicillin/
clarithromycin/
metronidazole/
tinidazole)+
14 1431 72.0 % vs.
69.8 %
1.17 (0.64–2.14) +
+same PPI (ome/esome/lanso/panto)
Yuan et al. 2009
China [34]
Dec 2008 HP infection;
naïve to
treatment
Italy, Croatia,
Turkey, China
Moxifloxacin-containing
triple: moxifloxacin+
Clarithromycin-
containing triple:
clarithromycin+
4 772 84.1 % vs.
73.6 %
1.13 (1.01–1.27)a +
+ same PPI (esome/lanso/ome) + another same regimen
(amoxicillin/tinidazole/metronidazole/bismuth-)
Zhang et al. 2013
China [47]
March
2012
HP infection;
PUD/NUD/
others; either
naive or with
previous
treatment
failures
Korea (2),
Croatia (2),
China, Italy,
Turkey
Moxifloxacin-containing
triple OR Quadruple:
moxifloxacin + amoxicillin/
metronidazole/tinidazole +/−
RBC+
Standard triple or
quadruple: (+/−)Bismuth/
RBC +metronidazole/
tinidazole/clarithromycin/
amoxicillin+
7 1263 79.0 % vs.
68.3 %
1.82 (1.17–2.81) +
+ same PPI (esome/ome/rabe/lanso)
Croatia, Turkey,
Italy
First-line First-line 3 717 Not
reported
1.80 (0.71–4.55)
Moxifloxacin-containing
triple OR Quadruple:
moxifloxacin + amoxicillin/
metronidazole/tinidazole
(+/−) RBC+
Standard triple or
quadruple: (+/−)
Bismuth/RBC +
metronidazole/tinidazole/
clarithromycin/amoxicillin
+
+ same PPI (esome/lanso)
Croatia, Korea
(2), China
Second-line Second-line 4 546 73.3 % vs.
60.2 %
1.78 (1.16–2.73)
Moxifloxacin-containing
triple: moxifloxacin +
metronidazole/amoxicillin+
Standard triple or
quadruple: (+/−) Bismuth
+metronidazole/
tinidazole/clarithromycin+
+ same PPI (esome/ome/rabe)
Croatia, Korea
(2), Turkey, Italy,
China
Moxifloxacin + amoxicillin
(+/−) RBC+
Standard triple or
quadruple: (+/−)
Bismuth/RBC +
metronidazole/tinidazole/
6 810 Not
reported
1.50 (0.95–2.38)
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Table 3 Characteristics of systematic reviews comparing triple therapy with different antibiotics (n = 8) (Continued)
clarithromycin/amoxicillin
+
+ same PPI(esome/ome/rabe/lanso)
Croatia (2), Italy Moxifloxacin +
metronidazole/tinidazole+
Standard triple or
quadruple: (+/−)
Bismuth/RBC +
metronidazole/tinidazole/
clarithromycin/amoxicillin
+
3 453 Not
reported
3.00 (1.84–4.89)
+ same PPI (esome/ome/rabe/lanso)
Ye et al. 2014 China
[35]
August
2013
HP infection;
naïve to
treatment
Germany, Egypt,
Taiwan (2),
China (2), Spain
(2), Italy (2)
Levofloxacin-containing
triple: levofloxacin+
Standard triple:
clarithromycin+
10 2676 81.5 % vs.
77.2 %
1.28 (0.88–1.85) ++
+same PPI(Ome/lanso/esome) + another one antibiotic
(amoxicillin/metronidazole)
Peedikayil et al. 2014
Saudi Arabia [36]
March
2013
HP infection;
naïve to
treatment
Egypt and Saudi
Arabia, Taiwan
(2), South Korea,
China, Italy (2)
Levofloxacin-containing
triple: levofloxacin+
Standard triple:
clarithromycin+
7 1782 79.1 % vs.
81.4 %
0.97 (0.93–1.02)a +
+same PPI(Ome/lanso/esome) + another one antibiotic
(amoxicillin/+metronidazole/clarithromycin/azithromycin)
Xiao et al. 2014 China
[37]
March
2013
HP infection;
naïve to
treatment,
PUD/NUD/not
reported
Italy (2), China
(3), Spain (2),
Egypt and Saudi
Arabia, Korea
Levofloxacin-containing
triple: levofloxacin+
Standard triple:
clarithromycin+
9 2512 80.2 % vs.
77.4 %
1.03 (0.94–1.13)a ++
+same PPI(Ome/lanso/esome) + another one antibiotic
(amoxicillin/+metronidazole/clarithromycin/azithromycin)
Gou et al. 2014 China
[26]
December
2013
HP infection;
naïve to
treatment
All from China Levofloxacin-containing
triple: levofloxacin+
Standard triple:
clarithromycin+
21 2697 82.3 %
vs.73.8 %
1.12 (1.08–1.16)a 0
No details reported
HP H.pylori, PPI proton pump inhibitor, esome esomeprazole, lanso lansoprazole, ome omeprazole, panto pantoprazole, rabe rabeprazole, PUD peptic ulcer disease, NUD non-ulcer dyspepsia, MA meta-analysis, ITT
intention to treat, CI confidence interval, RCT randomized controlled trials, RBC ranitidine bismuth citrate
a Relative risk is reported here
b Quality assessment: high quality (++): majority of criteria met, little or no risk of bias and results unlikely to be changed by further research. Acceptable (+): most criteria met, some flaws in the study with an
associated risk of bias and conclusions may change in the light of further studies. Low quality (0): either most criteria not met or significant flaws relating to key aspects of study design, and conclusions likely to
change in the light of further studies
c Countries of included RCTs: the number in the bracket represents the number of trials from the same country if more than one trial exists
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Table 4 Characteristics of systematic reviews comparing triple therapy versus bismuth-based therapy (n = 9)
Author, Year, country Last search
date
Disease Countries of
included RCTsf
Triple therapy Bismuth-based Quadruple
therapy
No. of
studies
in MA
No. of
patients
in MA
Eradication
rates by ITT
Eradication rates odds
ratio (95 % CI) by ITTd
Quality
assessmente
Gene et al. 2003
Spain [38]
Aug 2002 HP infection;
naïve to
therapy; PUD/
NUD
Spain (2), US/
Canada,
unknown
PPI (ome/panto) +
clarithromycin + amoxicillin
Bismuth + PPI(ome/panto)
+ tetracycline +
metronidazole
4 981 78 % vs.
81 %
0.83 (0.61–1.14)a 0
Gisbert et al. 2005
Spain [27]
Sep 2004 HP infection;
NUD+/−PUD;
previous
treatment
failures
Croatia, Spain
(6), Belgium,
Italy (4),
Greece, China
PPI (ome/lanso/panto) +
clarithromycin +
amoxicillin/nitroimidazole
RBC + clarithromycin +
amoxicillin
14 2205 78 % vs.
79 %
Bismuth vs. triple
1.11 (0.88–1.40)
+
Croatia, Italy
(6), Spain,
Norway,
Unknown (2),
The
Netherlands,
China
PPI (ome/lanso/panto/
rabe) + clarithromycin +
amoxicillin/nitroimidazole
RBC + clarithromycin +
nitroimidazole
13 1777 80 % vs.
87 %
Bismuth vs. triple
1.65 (1.15–2.37)
Taiwan, China,
UK
PPI (ome) + clarithromycin
+ amoxicillin/
nitroimidazole
RBC + nitroimidazole +
amoxicillin
3 451 75 % vs.
73 %
Bismuth vs. triple
0.92 (0.60–1.41)
Gisbert et al. 2006
Spain [28]
Jul 2005 HP infection;
Previous
treatment
failures
Italy (5), China,
Spain,
unknown
Levofloxacin-containing:
levofloxacin + PPI(panto/
rabe/esome/ome) +
amoxicillin/rifabutin
Bismuth + PPI(panto/rabe/
ome) + tetracycline +
metronidazole; or RBC+
tetracycline +
metronidazole
8 996 81 % vs.
70 %
1.80 (0.9–3.5) 0
Not reported Levofloxacin +
amoxicillin + PPI(panto/
rabe/esome/ome)
Bismuth + PPI(panto/rabe/
ome) + tetracycline +
metronidazole; or RBC+
tetracycline +
metronidazole
not
specified
Not
specified
Not
reported
1.7 (0.71–4.0)
Saad et al. 2006 US
[29]
Apr 2005 HP infection;
failed prior
course(s) of
standard triple
therapy
Italy (5), China Levofloxacin-containing:
levofloxacin+ +amoxicillin
+
Bismuth − +
metronidazole +
tetracycline+
6 854 87 % vs.
60 %
1.18 (1.08–1.29)b 0
+ same PPI (ome/esome/rabe/panto)
Li et al. 2010 China
[30]
1981-Mar
2009
(Published
date)
HP infection;
previous
treatment
failures
Germany (2),
Ireland
Clarithromycin-
containing: clarithromycin
+ amoxicillin+
Bismuth+ +metronidazole
+ tetracycline+
3 411 46.5 % vs.
61.9 %
0.53 (0.35–0.80) 0
+ same PPI (ome/not specified)
Korea (2),
Croatia
Moxifloxacin-containing:
moxifloxacin + amoxicillin/
metronidazole+
Bismuth +metronidazole
+ tetracycline+
3 437 Not
reported
1.78 (0.98–3.22)
+PPI(esome/ome)
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Table 4 Characteristics of systematic reviews comparing triple therapy versus bismuth-based therapy (n = 9) (Continued)
Taiwan, Korea,
China (5), Italy
(2)
Levofloxacin-containing:
levofloxacin + amoxicillin/
rifabutin+
Bismuth +metronidazole
+ tetracycline+
9 928 Not
reported
1.43 (0.82–2.51)
+ same PPI(esome/panto/lanso/rabe)
Luther et al. 2010 US
[50]
1990–2008
(Published
date)
HP infection Spain (2),
Greece,
Australia/New
Zealand, India,
US/Canada,
Korea, Turkey,
UK
Clarithromycin-
containing:
clarithromycin + amoxicillin
+
Bismuth +metronidazole
+ tetracycline +
9 1679 77.0 % vs.
78.3 %
Bismuth vs. triple
1.00 (0.94–1.07b
0
+PPI (ome/panto/lanso/not specified)
Wu et al. 2011 China
[31]
Dec 2010 HP infection;
previous
treatment
failures
China (4),
Korea (2),
Croatia
Moxifloxacin-containing:
Moxifloxacin + +
amoxicillin/metronidazole+
Bismuth +metronidazole/
furazolidone +
tetracycline/amoxicillin/
clarithromycin+
7 787 74.9 % vs.
61.4 %
1.89 (1.38–2.58) ++
+ PPI (esome/ome/rabe)
Di Caro et al. 2012
UK [32]
Oct 2010 HP infection;
previous
treatment
failures
Italy (4), Spain
(2), China (4),
Korea (2),
Taiwan,
Unknown
Levofloxacin +
amoxicillin-containing:
levofloxacin + amoxicillin +
PPI(panto/rabe/esome/
ome/lanso)
Bismuth quadruple
therapy (not specified)
14 1331 76.5 % vs.
67.4 %
1.59 (0.98–2.58) 0
Venerito et al. 2013
Germany [39]
Nov 2011 HP infection;
naïve to
therapy; PUD/
NUD/others
Spain (2),
Australia/New
Zealand,
Greece, US/
Canada, India,
Korea, Turkey
(2), UK, China,
multi European
countries
Clarithromycin-
containing:
clarithromycin + amoxicillin
+
Bismuth + tetracycline +
metronidazole+
12 2467 68.9 % vs.
77.6 %
Bismuth vs. triple
0.06 (−0.01–0.13)c
+
+PPI(ome/panto/lanso/not specified)
HP H.pylori, PPI proton pump inhibitor, esome esomeprazole, lanso lansoprazole, ome omeprazole, panto pantoprazole, rabe rabeprazole, PUD peptic ulcer disease, NUD non-ulcer dyspepsia, MA meta-analysis, ITT
intention to treat, CI confidence interval, RCT randomized controlled trials, RBC ranitidine bismuth citrate
a Peto OR is reported here
b Relative risk is reported here
c Risk difference is reported here
d OR > 1 indicates that triple therapy is associated with greater effectiveness than bismuth-based therapy and vice versa. When “Bismuth vs. triple” is specified in the form, OR > 1 indicates bismuth-based therapy is as-
sociated with greater effectiveness than triple therapy and vice versa
e Quality assessment: high quality (++): majority of criteria met, little or no risk of bias and results unlikely to be changed by further research. Acceptable (+): most criteria met, some flaws in the study with an
associated risk of bias and conclusions may change in the light of further studies. Low quality (0): either most criteria not met or significant flaws relating to key aspects of study design, and conclusions likely to
change in the light of further studies
f Countries of included RCTs: the number in the bracket represents the number of trials from the same country if more than one trials exist
Xin
et
al.BM
C
G
astroenterology
 (2016) 16:80 
Page
12
of
18
Table 5 Characteristics of systematic reviews comparing PPI and H2 receptor antagonists (H2RAs) (n = 3)
Author, year, country Last search
date
Disease H2RAs PPI No. of
studies in
MA
No. of
patients in
MA
Eradication
rates by ITT
Eradication rates odds
ratio (95 % CI) by ITT
Quality
assessmenta
Gisbert et al. 2003
Spain [40]
Jan 2002 HP infection;
naïve to
treatment;
PUD/NUD
H2RAs (ranitidine/
famotidine/
nizatidine)+
PPI (ome/lanso)+ 20 2374 69 % vs.
74 %
Triple vs. H2RAs 1.31
(1.09-1.58)
+
+ two same antibiotics (amoxicillin/clarithromycin/
metronidazole/tinidazole) +/− bismuth-
Graham et al. 2003
US [53]
1990–2001
(Published
date)
HP infection;
either naïve or
with previous
treatment
failures
H2RAs(nizatidine/
famotidine/ranitidine)
+
PPI (lanso/ome) + 12 1441 78 % vs.
81 %
0.83 (0.63–1.09) 0
+ two same antibiotics (clarithromycin/amoxicillin/
metronidazole/tinidazole)
H2RAs(not specified)+ Clarithromycin-containing triple:
Clarithromycin + PPI(not specified)+
6 Not
reported
79 % vs.
69 %
1.14 (0.76–1.71)
+ one same antibiotics (not specified)
H2RAs(not specified)+ Clarithromycin NOT-containing
triple: PPI(not specified)+
6 Not
reported
78 % vs.
85 %
0.64 (0.45–0.92)
+two same antibiotics (not specified)
Ren et al. 2010 China
[41]
Apr 2010 HP infection;
naïve to
treatment
Lafutidine-
containing:
H2RAs(lafutidine)+
Lanso-containing triple: PPI(lanso) + 3 238 78 % vs.
77.5 %
1.03 (0.64–1.66) ++
+ two same antibiotics (clarithromycin + amoxicillin)
HP H.pylori, H2RAs H2 receptor antagonists, PPI proton pump inhibitor, esome esomeprazole, lanso lansoprazole, ome omeprazole, panto pantoprazole, rabe rabeprazole, PUD peptic ulcer disease, NUD non-ulcer dys-
pepsia, MA meta-analysis, ITT intention to treat, CI confidence interval, RCT randomized controlled trials
a Quality assessment: high quality (++): majority of criteria met, little or no risk of bias and results unlikely to be changed by further research. Acceptable (+): most criteria met, some flaws in the study with an
associated risk of bias and conclusions may change in the light of further studies. Low quality (0): either most criteria not met or significant flaws relating to key aspects of study design, and conclusions likely to
change in the light of further studies
Xin
et
al.BM
C
G
astroenterology
 (2016) 16:80 
Page
13
of
18
Table 6 Characteristics of systematic reviews comparing other regimens (n = 3)
Author, year, country Last search
date
Disease Countries of
included RCTsb
Intervention Comparison No. of
studies
in MA
No. of
patients
in MA
Eradication
rates by ITT
Eradication rates odds
ratio (95 % CI) by ITT
Quality
assessmenta
Gisbert and Calvet 2012
Spain [48]
December
2011
HP infection
PUD/NUD/
others
Germany, UK,
Japan, Italy,
Japan, Korea
(2)
Concomitant therapy:
metronidazole +
standard triple therapy
Standard triple therapy 7 984 90 % vs.
78 %
2.36 (1.67–3.34) 0
Note: Standard triple therapy: (PPI(ome/rabe/lanso)
+ amoxicillin + clarithromycin)
Lv et al. 2015 China [49] April 2014 HP infection;
PUD/NUD/
others; naïve to
treatment or
had previous
treatment
China (4),
Taiwan (3),
Korea, Turkey
Quadruple regimens
containing both
amoxicillin and
tetracycline
Other quadruple regimens
where amoxicillin and
tetracycline were not
contained together
9 1453 78.1 % vs.
80.5 %
0.90 (0.46–1.78) +
US, Italy,
Turkey, Taiwan,
China
Triple therapy
containing both
amoxicillin and
tetracycline
Other regimens where
amoxicillin and
tetracycline were not
contained together
5 840 68.8 % vs.
66.7 %
1.21 (0.64–2.28)
Nishizawa et al. 2014 Japan
[54]
July 2014 HP infection Japan (5),
Korea
Rebamipide
containing regimen:
rebamipide+
Rebamipide NOT-
containing regimen:
none or mucosal
protective agents other
than rebamipide
(teprenone/plaunotol)+
6 611 63.5 % vs.
52.7 %
1.59 (1.14–2.22) +
+PPI(lanso/ome) + antibiotics (amoxicillin/
metronidazole)
HP H.pylori, PPI proton pump inhibitor, esome esomeprazole, lanso lansoprazole, ome omeprazole, panto pantoprazole, rabe rabeprazole, PUD peptic ulcer disease, NUD non-ulcer dyspepsia, MA meta-analysis, ITT
intention to treat, CI confidence interval, RCT randomized controlled trials
a Quality assessment: high quality (++): majority of criteria met, little or no risk of bias and results unlikely to be changed by further research. Acceptable (+): most criteria met, some flaws in the study with an
associated risk of bias and conclusions may change in the light of further studies. Low quality (0): either most criteria not met or significant flaws relating to key aspects of study design, and conclusions likely to
change in the light of further studies
b Countries of included RCTs: the number in the bracket represents the number of trials from the same country if more than one trials exist
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of the included studies is presented in Additional file 4:
Table S2.
Discussion
Summary of findings
This overview of systematic reviews evaluated the effect-
iveness of pharmacological regimens for the eradication
of H.pylori by searching and analysing the existing sys-
tematic reviews from 2002 to present. In triple therapy,
regarding the use of different PPIs, we found that the re-
sults of studies were inconsistent; however more recently
published studies tend to suggest new generation PPIs
were associated with greater eradication rates than the
old generation. The NMA suggested that esomeprazole
was the most effective PPI with the highest probability
to be the best among the five PPIs after incorporating
evidence of both direct and indirect comparisons. Re-
garding the use of antibiotics, conflicting results exist
between the studies to some extent; however this could
be due to the varied resistant rate to different antibiotics
across regions. This leads to the limited transferability of
RCT results across countries and population and thus,
there exist issues of fundamental heterogeneity when
pooling results together in the meta-analysis. Concern-
ing the comparison between triple therapy and bismuth-
based therapy, there was no difference between the two
regimens overall, but the antibiotics within the triple
therapy may have an impact on the overall effectiveness
of the drug regimen. Moxifloxacin or levofloxacin based
triple therapy were associated with greater eradication
rates, lower risk of adverse events and lower discontinu-
ation rate than bismuth-based therapy for second-line
treatment. With regard to the comparison between triple
therapies and H2 receptor antagonist and others, no def-
inite conclusion could be reached due to limited avail-
able evidence.
The evidence on the effectiveness of PPI has evolved
over time. Contrary to existing guidance, recent studies
have shown that the new generation PPIs have achieved
statistically significant greater effectiveness rate than the
old generations. There is a clear time trend when evalu-
ating the systematic reviews – systematic reviews pub-
lished before 2006 reported no difference, while 2006
onwards, the statistical significant difference was shown
in the pooled results. This can be explained by more re-
cent RCTs and a more complete evidence base included
in the recent systematic reviews (Additional file 5: Table
S3). When comparing between triple therapy and
bismuth-based therapy, the results were mixed. How-
ever, there seems to be a trend according to the choice
of antibiotics in triple therapy – triple therapy achieved
greater eradication rates than bismuth-based therapy
when moxifloxacin or levofloxacin was used as a substi-
tute of clarithromycin for second-line treatment.
Although generally the results of comparing triple ther-
apy and bismuth-based therapy failed to show statistical
significance, it is possible this is a sample size issue. Our
results support the current guidance on the recommen-
dations of moxifloxacin or levofloxacin as the second-
line treatment for previous treatment failures of H.pyl-
ori. However, its role as a first-line therapy was found to
be controversial. Two studies showed the use of levo-
floxacin or moxifloxacin for treating naïve patients was
associated with improved eradication rate [25, 26], while
three studies found no difference [35–37]. This was fur-
ther investigated by two subgroup analyses from two in-
cluded studies which both suggested that levofloxacin
achieved statistically greater eradication rates in Euro-
pean countries where the resistant rates were much
lower than the global average [35, 37]. Therefore, the
discrepancy of the results could be attributed to the var-
ied resistant rates to different antibiotics across regions
or populations. This could also possibly explain that the
two meta-analyses which pooled RCTs mostly from
China showed the improved effectiveness of levofloxacin
as first-line treatment [25, 26] – the resistant rate to
clarithromycin could be possibly much higher than that
to levofloxacin in the regions where the included RCTs
were conducted.
Comparison with current guidelines
Based on current guidelines from the American College of
Gastroenterology, Canadian Helicobacter Study Group
and National Institute for Health and Care Excellence
(NICE), a triple regimen consisting of a PPI, clarithromy-
cin with either metronidazole or amoxicillin is recom-
mended as first-line treatment [13–15]. In addition, both
of the American and Canadian guidelines recommend the
combination of PPI, bismuth, tetracycline and metronida-
zole as an alternative for first-line therapy [13, 14]. The
alternative of bismuth quadruple therapy is raised due
to the increasing clarithromycin resistance rate which
has lowered the efficacy of triple therapy to 70–85 %.
The American guideline also recommends to consider
levofloxacin-based triple therapy when bismuth or
clarithromycin-based therapies are not an option in some
circumstances [14]. In 2009, the Asia–Pacific H.pylori
Consensus Conference agreed that the first-line treatment
should consist of either clarithromycin-based triple or bis-
muth quadruple therapy, and further proposed four op-
tions for second-line treatment: (i) standard triple therapy
that has not been previously used; (ii) bismuth-based
quadruple therapy; (iii) levofloxacin-based triple therapy;
and (iv) rifabutin-based triple therapy [55].
The European Helicobacter Study Group published
their latest guideline in 2012 – the Maastricht IV report
[12] recommending specific H.pylori eradication strat-
egies according to different clarithromycin resistance
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rates. The threshold for classifying clarithromycin resist-
ance to the high/low area is set as 15 % –20 %. In regions
with low clarithromycin resistance rates, clarithromycin-
based triple therapy remains the first-line treatment, with
the alternative of bismuth quadruple therapy. Where there
is higher clarithromycin resistance, the bismuth-based
therapy is recommended as the first-line treatment. In
both circumstances, levofloxacin is recommended for
second-line therapy rather than first-line for the reason
of ’rapid acquisition of resistance’.
The World Gastroenterology Organization published
their H.pylori guideline for developing countries in 2011,
which is consistent with the above guidelines. However,
it states that, due to its low cost, furazolidone may be
served as an alternative option by developing countries,
such as Brazil and China, despite being withdrawn in the
US and the European Union due to the severe adverse
events [56].
It is worth noting that the type of PPI is not specified in
any of the current guidelines, which may be due to the
limited availability of reliable evidence from studies when
those guidelines were published. However, our review
showed that the esomeprazole could achieve greater eradi-
cation rate than the older generation of PPIs. Despite the
relatively high cost of newer generation of PPI, this differ-
ence in effectiveness between the generations of PPIs
should be taken into account in the recommendations.
Our finding supported the recommendation of bismuth-
based therapy as a first-line alternative to standard triple
therapy in a high clarithromycin resistant area. For the
second-line treatment, our findings are consistent with
the current guidelines; both moxifloxacin/levofloxacin
containing triple therapy and bismuth-based therapy can
achieve higher eradication rates than clarithromycin-
containing triple therapy. Moreover, the former appeared
to be superior to the latter in terms of eradication rates
and adverse events rates.
Limitations
There are a few limitations of this study. As this is an
overview of systematic reviews, our results are dependent
on what has been reported in the included systematic re-
views and on the methodological rigour applied in their
development. For instance, similar search strategy across
systematic reviews has turned out to include difference
RCTs. The low-moderate overall quality of included stud-
ies may affect the impact of this overview of systematic re-
views on clinical decision making. However, it is difficult
to judge whether the low internal validity of the individual
systematic reviews resulted from insufficient reporting or
certain methodological flaws. In addition, there were some
heterogeneity issues in this overview. The systematic re-
views have included a mixture of population characteris-
tics, countries of origin and comorbidities, infection
epidemiology and antibiotics resistance type and thus the
eradication rates varied with those factors. This may not
be appropriately considered and addressed in some of the
included meta-analysis, leading to the inconsistent results
in our findings.
Conclusions
This overview of systematic reviews suggests that the
new generation of PPIs and use of moxifloxacin or levo-
floxacin in triple therapy or bismuth-based therapy as
second-line treatment were associated with greater ef-
fectiveness, while the comparative effectiveness of antibi-
otics is complex which probably depends on the
resistant rate to different antibiotics in different regions.
This should be explored in future research for updating
the guidelines. In addition, considering the substantiated
difference in the cost of treatment, estimating the cost-
effectiveness of these treatments is of value to clinical
decision making, especially in the area with high H.pyl-
ori prevalence. Given the variation in infection epidemi-
ology and increasing antibiotics resistance, from a
clinical perspective, the recommendations should be lo-
calized based on the specific prevalence of H.pylori in-
fection and antibiotics resistance rate in the local region
and population.
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